Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial
- 1 March 2008
- journal article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 3 (5) , 566-573
- https://doi.org/10.4244/eijv3i5a102
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 21 references indexed in Scilit:
- Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)The American Journal of Cardiology, 2006
- Coronary-Artery StentsNew England Journal of Medicine, 2006
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary ArticleJournal of the American College of Cardiology, 2005
- Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)The American Journal of Cardiology, 2005
- Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable PolymerCirculation, 2004
- Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex PatientsCirculation, 2004
- Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting StentsCirculation, 2001
- Interlesion Dependence of the Risk for Restenosis in Patients With Coronary Stent Placement in Multiple LesionsCirculation, 1998
- Guidelines for percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1993
- Guidelines for percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1988